ePrints

2023 FDA TIDES (Peptides and Oligonucleotides) Harvest

Lookup NU author(s): Dr Othman AlmusaimiORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

A total of nine TIDES (pepTIDES and oligonucleoTIDES) were approved by the FDA during 2023. The approved four oligonucleotide are indicated for various types of disorders, including amyotrophic lateral sclerosis, geographic atrophy, primary hyperoxaluria type 1, and polyneuropathy of hereditary transthyretin-mediated amyloidosis. All oligonucleotides showed chemically modified structures, to enhance their stability and therapeutic effectiveness as antisense or aptamer oligomers. Some of them demonstrate various types of conjugation to driving ligands. The approved peptides comprise various structures including linear, cyclic, lipopeptides and with diverse applications. Interestingly, the FDA has granted an orphan drug designation for a first peptide-based drug as a highly selective chemokine antagonist. Furthermore, Rett syndrome has found its first ever core symptoms treatment, which is also peptide-based one. Here we analyse the TIDES approved in 2023 on the basis of their chemical structure, medical target, mode of action, administration route, and common adverse effects.

Publication metadata

Author(s): Al Musaimi O, Al Shaer D, Albericio F, de la Torre BG

Publication type: Article

Publication status: Published

Journal: Pharmaceuticals

Year: 2024

Volume: 17

Issue: 2

Online publication date: 13/02/2024

Acceptance date: 09/02/2024

Date deposited: 21/02/2024

ISSN (electronic): 1424-8247

Publisher: MDPI

URL: https://doi.org/10.3390/ph17020243

DOI: 10.3390/ph17020243

Altmetrics

Funding

Share